| Table1. All baseline demographics and disease characteristics of patients with VETC+ and VETC-. | ||||
| Characteristic | Overall N = 123 |
VETC- N = 86 |
VETC+ N = 37 |
p-value1 |
|---|---|---|---|---|
| Age, Mean ± SD | 50.86 ± 12.13 | 51.55 ± 11.83 | 49.26 ± 12.83 | 0.357 |
| Gender, n (%) | 0.179 | |||
| Female | 18.00 (14.63) | 15.00 (17.44) | 3.00 (8.11) | |
| Male | 105.00 (85.37) | 71.00 (82.56) | 34.00 (91.89) | |
| HBV infection, n (%) | 101.00 (82.11) | 68.00 (79.07) | 33.00 (89.19) | 0.179 |
| HCV infection, n (%) | 2.00 (1.63) | 2.00 (2.33) | 0.00 (0.00) | >0.999 |
| ECOG PS, n (%) | 0.340 | |||
| 0 | 105.00 (85.37) | 73.00 (84.88) | 32.00 (86.49) | |
| 1 | 17.00 (13.82) | 13.00 (15.12) | 4.00 (10.81) | |
| 3 | 1.00 (0.81) | 0.00 (0.00) | 1.00 (2.70) | |
| Post-radical surgery, n (%) | 65.00 (52.85) | 37.00 (43.02) | 28.00 (75.68) | <0.001 |
| Post-immunotherapy, n (%) | 13.00 (10.57) | 7.00 (8.14) | 6.00 (16.22) | 0.208 |
| Post-chemotherapy, n (%) | 54.00 (43.90) | 29.00 (33.72) | 25.00 (67.57) | <0.001 |
| Tumor Num, n (%) | 0.948 | |||
| <3 | 17.00 (13.82) | 12.00 (13.95) | 5.00 (13.51) | |
| ≥3 | 106.00 (86.18) | 74.00 (86.05) | 32.00 (86.49) | |
| Tumor Size, n (%) | 0.008 | |||
| <5 | 64.00 (52.03) | 38.00 (44.19) | 26.00 (70.27) | |
| ≥5 | 59.00 (47.97) | 48.00 (55.81) | 11.00 (29.73) | |
| Lymphatic metastasis, n (%) | 63.00 (51.22) | 48.00 (55.81) | 15.00 (40.54) | 0.120 |
| Distant metastasis, n (%) | 82.00 (66.67) | 57.00 (66.28) | 25.00 (67.57) | 0.889 |
| Presentation of PVTT, n (%) | 46.00 (37.40) | 39.00 (45.35) | 7.00 (18.92) | 0.005 |
| BCLC stage, n (%) | 0.429 | |||
| 0/A | 7.00 (5.69) | 4.00 (4.65) | 3.00 (8.11) | |
| B/C | 116.00 (94.31) | 82.00 (95.35) | 34.00 (91.89) | |
| TNM stage, n (%) | 0.046 | |||
| Ⅰ/Ⅱ | 18.00 (14.63) | 9.00 (10.47) | 9.00 (24.32) | |
| Ⅲ/Ⅳ | 105.00 (85.37) | 77.00 (89.53) | 28.00 (75.68) | |
| AFP, n (%) | 0.172 | |||
| <400 | 68.00 (55.28) | 51.00 (59.30) | 17.00 (45.95) | |
| ≥400 | 55.00 (44.72) | 35.00 (40.70) | 20.00 (54.05) | |
| PIVKA-Ⅱ, n (%) | 0.429 | |||
| <100 | 36.00 (29.27) | 27.00 (31.40) | 9.00 (24.32) | |
| ≥100 | 87.00 (70.73) | 59.00 (68.60) | 28.00 (75.68) | |
| WBC, Median (Q1, Q3) | 6.27 (5.11, 8.07) | 6.59 (5.06, 8.07) | 5.98 (5.40, 7.18) | 0.669 |
| NE, Median (Q1, Q3) | 4.13 (3.04, 5.90) | 4.39 (3.03, 5.95) | 3.94 (3.08, 4.82) | 0.302 |
| LY, Mean ± SD | 1.61 ± 0.66 | 1.58 ± 0.66 | 1.67 ± 0.65 | 0.443 |
| Platelet, Median (Q1, Q3) | 183.00 (131.00, 248.00) | 185.50 (131.00, 269.00) | 181.00 (132.00, 211.00) | 0.741 |
| NLR, n (%) | 0.271 | |||
| <3.3 | 74.00 (60.16) | 49.00 (56.98) | 25.00 (67.57) | |
| ≥3.3 | 49.00 (39.84) | 37.00 (43.02) | 12.00 (32.43) | |
| PLR, n (%) | 0.094 | |||
| <117 | 59.00 (47.97) | 37.00 (43.02) | 22.00 (59.46) | |
| ≥117 | 64.00 (52.03) | 49.00 (56.98) | 15.00 (40.54) | |
| PT, Median (Q1, Q3) | 12.30 (11.60, 13.10) | 12.35 (11.60, 13.10) | 12.30 (11.60, 12.90) | 0.847 |
| CRP, Median (Q1, Q3) | 9.27 (2.24, 28.02) | 9.44 (2.64, 28.01) | 8.88 (1.77, 28.38) | 0.629 |
| ALT, Median (Q1, Q3) | 42.80 (24.30, 68.60) | 37.65 (24.10, 60.80) | 46.80 (27.90, 81.20) | 0.082 |
| AST, Median (Q1, Q3) | 46.60 (30.60, 76.60) | 48.55 (29.30, 76.60) | 42.10 (34.70, 76.20) | 0.884 |
| TBIL, Median (Q1, Q3) | 13.40 (10.30, 18.20) | 13.30 (10.10, 17.50) | 13.60 (11.60, 18.90) | 0.328 |
| ALB, Median (Q1, Q3) | 42.70 (38.00, 45.20) | 42.45 (37.30, 45.10) | 43.50 (39.90, 46.40) | 0.187 |
| ALBI, n (%) | 0.561 | |||
| 1 | 85.00 (69.11) | 57.00 (66.28) | 28.00 (75.68) | |
| 2 | 36.00 (29.27) | 27.00 (31.40) | 9.00 (24.32) | |
| 3 | 2.00 (1.63) | 2.00 (2.33) | 0.00 (0.00) | |
| Child-Pugh, n (%) | 0.667 | |||
| 1 | 117.00 (95.12) | 81.00 (94.19) | 36.00 (97.30) | |
| 2 | 6.00 (4.88) | 5.00 (5.81) | 1.00 (2.70) | |
| 1 Welch Two Sample t-test; Pearson’s Chi-squared test; Fisher’s exact test; Kruskal-Wallis rank sum test | ||||